DNUT - Krispy Kreme's Insomnia Divestiture May Not Boost Core Focus As Expected: Analyst Weighs In | Benzinga
Truist Securities analyst Bill Chappell reiterated a Buy rating on the shares of Krispy Kreme Inc (NASDAQ: DNUT) with an unchanged price target of $20.
Yesterday, the company announced that it is seeking strategic alternatives for its Insomnia Cookies to "unlock shareholder value and focus on its core strategy of producing, selling and distributing fresh doughnuts daily."
Related: Krispy Kreme Considers Selling Insomnia Cookies Business For The Love Of Fresh Doughnuts
Insomnia operates over 250 small bakeries, mostly in college towns and urban ...